医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Avita Medical Named to 2017 OTCQX Best 50

2017年03月01日 AM08:13
このエントリーをはてなブックマークに追加


 

VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England

Avita Medical Limited (ASX:AVH) (OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, is pleased to announce it has been named to the 2017 OTCQX® Best 50, a ranking of top performing companies traded on the U.S. OTCQX Best Market last year.

The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX market. The ranking is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the previous calendar year. Companies in the 2017 OTCQX Best 50 were ranked based on their performance in 2016.

Commenting on the recognition, Adam Kelliher, CEO of Avita Medical, stated, “This past year has been a transitional year for us as we position our lead product in front of US FDA approval. We are pleased that our efforts have been recognized by the investment community, and we look forward to continuing to drive shareholder value by the successful execution of our strategic growth plans throughout 2017 and beyond.”

For the complete 2017 OTCQX Best 50 ranking, visit: http://web.otcmarkets.com/otcqx-best-50/.

The OTCQX Best Market offers transparent and efficient trading of established, investor-focused U.S. and global companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and have a professional third-party sponsor introduction. The companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The Company’s lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170228006924/en/

CONTACT

Avita Medical Ltd
Adam Kelliher, +44 020 8947 9804
Chief
Executive Officer
akelliher@avitamedical.com
or
Avita
Medical Ltd

Tim Rooney, +1 (661) 367-9170
Chief Financial
Officer
trooney@avitamedical.com
or
Australia
Monsoon
Communications

Sarah Kemter, +61 (0)3 9620 3333
sarahk@monsoon.com.au
Mobile:
+61 (0)407 162 530
or
USA
Westwicke Partners
Jamar
Ismail, +1 (415) 513-1282
jamar.ismail@westwicke.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Heliae Announces First Use of Branded TruAzta Natural Astaxanthin
  • Visioneering Technologies, Inc. Successfully Lists on ASX
  • 中国のヘルスケア市場は今後15年間で投資と機会が急拡大の見込み
  • Dr. Reddy’s and Integra LifeSciences Enter into an Agreement to Market and Distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration in India
  • Latest clinical research confirms that IQOS reduces smoker exposure to select harmful chemicals as compared to cigarette smoke